Abstract
Risk assessment for a cancer type with moderate heritability can be accurately performed using a relatively small number of SNPs detected by GWAS analyses to calculate a polygenic risk score (PRS) that has definite clinical utility.
Subject
General Biochemistry, Genetics and Molecular Biology,General Medicine